Oxycontin maker Purdue Pharma considered expanding into opioid addiction treatment, according a previously sealed document filed by Massachusetts officials. Purdue executives discussed how the sale of opioids and addiction are linked, therefore making it an “attractive market,” according to the documents, filed as part of the state’s complaint against Purdue and company directors accusing them of creating the opioid epidemic. (STAT)

Mylan has received FDA approval for its generic version of GlaxoSmithKline’s Advair, an asthma and COPD drug. Mylan will market the inhaler for patients ages four and older as a twice-daily treatment. Novartis, Hikma Pharmaceuticals, and Mylan’s generics for Advair have been rejected by the FDA. (Reuters)

House Democrats sent letters on Wednesday to three drugmakers about the increasing cost of insulin. Eli Lilly, Novo Nordisk, and Sanofi must respond by providing information on insulin prices and explain obstacles that prevent making it more affordable by February 13. (CNBC)

E-cigarettes were almost twice as effective at helping individuals quit smoking as other nicotine-replacement products such as patches and gum, according to a study published in the New England Journal of Medicine on Wednesday. The study, conducted in the U.K., found that 18% of people who used e-cigarettes successfully quit, in comparison to 9.9% who used other products. (New York Times)

Today is the last day to submit your nomination for MM&M’s 2019 Top 40 Healthcare Transformers and Top 10 Innovation Catalysts. This year’s classes will be revealed in March, profiled in the May issue, and honored on May 7 in New York City. (MM&M)